The WARN noted some of the employees may be able to find “alternative positions” within the company but called the layoffs permanent and said they’d mostly go into effect Nov. 1. “BioMarin ...

BioMarin Pharmaceutical, a biotech firm based in San Rafael that specializes in treatments for rare diseases, is set to lay ...

The sweeping changes introduced by new BioMarin chief executive Alexander Hardy continue apace, with a second round of layoffs that will cut another 225 positions from its total headcount.

Revenue for Q2 2024 totaled $712 million, a 20% year-over-year increase. Management raised full-year 2024 guidance, reflecting the company's optimistic outlook. Key products Voxzogo and enzyme ...

A month has gone by since the last earnings report for BioMarin Pharmaceutical (BMRN). Shares have added about 4.2% in that time frame, outperforming the S&P 500. Will the recent positive trend ...

Stock analysts at Zacks Research increased their Q1 2025 earnings per share estimates for BioMarin Pharmaceutical in a research note issued on Wednesday, March 12th. Zacks Research analyst S. Ganoria ...

BioMarin Pharmaceutical (NASDAQ:BMRN), a leader in developing innovative therapies for rare genetic disorders, reported fourth-quarter 2024 financial results on Wednesday, Feb. 19, that topped ...